Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025Frontiers in OncologyOpen Access

TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMarwah Albakri

Discussion

Loading...

Member takes

Overview

Review highlights immune dysregulation in MDS and AML with TP53 mutations, suggesting novel therapeutic strategies.

Key Points

  • Immune dysfunction significantly affects outcomes in patients with TP53-mutated MDS and AML, leading to treatment resistance.
  • Current therapies show limited effectiveness, with poor survival rates reported in affected individuals.
  • Targeted therapies, including immune modulation and pathway inhibitors, emerge as promising options for effective treatment.
  • Integrating metabolic and immune-modulating therapies may improve outcomes for patients with these high-risk conditions.

Cite This Study

Marwah Albakri (2025) studied this question.

synapsesocial.com/papers/68af4093cf1dd9ea359ec48fhttps://doi.org/10.3389/fonc.2025.1655486
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations2025
  2. 2Targeting DNA repair vulnerabilities to eradicate TP53 mutated AML.2025
  3. 3Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  4. 4TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends2025
  5. 5The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune response2025